tirzepatide and crohn's disease COMMIT-CD: A Phase 3b trial evaluating the efficacy & safety of concomitant use of a dual GLP-1/GIP receptor agonist & IL-23p19 antagonist in adult participants with moderately to severely active Does Tirzepatide Help With Autoimmune

2007 e.T9865A13022716

Its obesity data come from a Phase 2 randomized trial published in the New England Journal of Medicine in 2023 by Jastreboff and colleagues, which enrolled 338 adults with obesity over 48 weeks

This was the first study suggesting a disturbance of glutamatergic transmission in RLS, and suggesting the mechanisms of action of glutamatergic drugs (that is, 2 ligands) and other arousal-reducing agents

Calculate the recovery by comparing the measured value with the expected amount of GLP-1 in the sample

It is not suitable for type 1 diabetes, diabetic ketoacidosis, or as firstline monotherapy when diet and exercise alone have not been evaluated